2ND MALIGNANT-TUMORS FOLLOWING TREATMENT DURING CHILDHOOD AND ADOLESCENCE FOR CANCER

被引:71
作者
GREEN, DM
ZEVON, MA
REESE, PA
LOWRIE, GS
GAETA, JF
PEARCE, JI
MICHALEK, AM
STEPHENS, EA
机构
[1] ROSWELL PK CANC INST,DEPT PSYCHOL,BUFFALO,NY 14263
[2] ROSWELL PK CANC INST,DEPT BIOSTAT,BUFFALO,NY 14263
[3] ROSWELL PK CANC INST,DEPT PATHOL,BUFFALO,NY 14263
[4] ROSWELL PK CANC INST,DEPT RADIAT MED,BUFFALO,NY 14263
[5] ROSWELL PK CANC INST,DEPT EDUC,BUFFALO,NY 14263
[6] SUNY BUFFALO,SCH MED,DEPT PEDIAT,BUFFALO,NY 14214
[7] SUNY BUFFALO,SCH MED,DEPT PATHOL,BUFFALO,NY 14214
[8] SUNY BUFFALO,ROSWELL PK GRAD DIV,DEPT NAT SCI,BUFFALO,NY 14260
来源
MEDICAL AND PEDIATRIC ONCOLOGY | 1994年 / 22卷 / 01期
关键词
MULTIPLE PRIMARY NEOPLASMS; DOXORUBICIN; NITROSOUREA COMPOUNDS; ANTINEOPLASTIC AGENTS; RADIATION INDUCED NEOPLASMS; NERVOUS TISSUE NEOPLASMS;
D O I
10.1002/mpo.2950220102
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Many pediatric and adolescent cancer patients are treated with carcinogenic chemotherapeutic agents and radiation therapy to achieve permanent control of their malignancy. These modalities may induce a new cancer in the successfully treated patient. To identify disease and treatment factors which increased the risk of occurrence of a second malignant tumor following modern treatment for cancer during childhood or adolescence, we reviewed the courses of 1,406 previously untreated patients who were less than 20 years of age at diagnosis and were treated at Roswell Park Cancer Institute between January 1, 1960 and December 31, 1989. Eighteen patients developed a second malignant tumor, including two meningiomas, 2.65-25.65 years after diagnosis of the first cancer. The actuarial risk of a second malignant tumor was 5.6% at 25 years after diagnosis. Using Cox proportional hazards modelling, we identified prior therapy with BCNU (P = 0.0055) and doxorubicin (P = 0.0254) as the only factors that were significantly associated with the risk of a second malignant tumor. Three second malignant tumors of the central nervous system occurred following treatment with a nitrosourea. Successfully treated patients must be carefully followed to identify treatment related malignant tumors at an early stage. (C) 1994 Wiley-Liss, Inc.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 69 条
  • [1] MUTAGENICITY OF NITROSOUREA COMPOUNDS FOR SALMONELLA-TYPHIMURIUM
    AULETTA, AE
    MARTZ, AG
    PARMAR, AS
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1978, 60 (06) : 1495 - 1497
  • [2] BAILAR JC, 1964, BIOMETRICS, V20, P639
  • [3] BENEDICT WF, 1977, CANCER RES, V37, P2209
  • [4] LEUKEMIA AND PRELEUKEMIA AFTER ADJUVANT TREATMENT OF GASTROINTESTINAL CANCER WITH SEMUSTINE (METHYL-CCNU)
    BOICE, JD
    GREENE, MH
    KILLEN, JY
    ELLENBERG, SS
    KEEHN, RJ
    MCFADDEN, E
    CHEN, TT
    FRAUMENI, JF
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (18) : 1079 - 1084
  • [5] BUCCIARELLI E, 1981, JNCI-J NATL CANCER I, V66, P81
  • [6] BURNETT WS, 1987, CANCER INCIDENCE COU, V1
  • [7] 2ND PRIMARY-CANCER FOLLOWING HODGKINS-DISEASE - UPDATED RESULTS OF AN ITALIAN MULTICENTRIC STUDY
    CIMINO, G
    PAPA, G
    TURA, S
    MAZZA, P
    FERRINI, PLR
    BOSI, A
    AMADORI, S
    LOCOCO, F
    DARCANGELO, E
    GIANNARELLI, D
    MANDELLI, F
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (03) : 432 - 437
  • [8] COHEN RJ, 1976, CANCER TREAT REP, V60, P1257
  • [9] DAVIS LE, 1988, OBSTET GYNECOL, V71, P506
  • [10] LONG-TERM RISK OF 2ND MALIGNANT NEOPLASM AFTER A CANCER IN CHILDHOOD
    DEVATHAIRE, F
    SCHWEISGUTH, O
    RODARY, C
    FRANCOIS, P
    SARRAZIN, D
    OBERLIN, O
    HILL, C
    RAQUIN, MA
    DUTREIX, A
    FLAMANT, R
    [J]. BRITISH JOURNAL OF CANCER, 1989, 59 (03) : 448 - 452